OTCMKTS:IMLFF

InMed Pharmaceuticals (IMLFF) Stock Price, News & Analysis

$0.25
-0.05 (-16.56%)
(As of 04/25/2024 ET)
Today's Range
$0.25
$0.27
50-Day Range
$0.27
$0.44
52-Week Range
$3.04
$10.63
Volume
623,391 shs
Average Volume
11,369 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
IMLFF stock logo

About InMed Pharmaceuticals Stock (OTCMKTS:IMLFF)

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of orofacial pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, it works on IND-enabling pharmacology and preclinical toxicology studies. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.

IMLFF Stock Price History

IMLFF Stock News Headlines

“Retirement Secret” Showed 995% Gain Last Time We Shared It
Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.
INM InMed Pharmaceuticals Inc.
InMed Provides Business Update and Milestones for 2023
“Retirement Secret” Showed 995% Gain Last Time We Shared It
Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.
What You Need To Know About CBD Hash
See More Headlines
Receive IMLFF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InMed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
OTCMKTS:IMLFF
CIK
N/A
Fax
N/A
Employees
4
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Mr. Eric A. Adams (Age 56)
    Pres, CEO & Director
  • Mr. Bruce S. Colwill C.A. (Age 55)
    CPA, CA, CFO & Corp. Sec.
  • Ms. Alexandra D. J. Mancini (Age 67)
    Sr. VP of Clinical & Regulatory Affairs
  • Dr. Eric Chih-Hsien Hsu (Age 50)
    Sr. VP of Preclinical R&D
  • Mr. Michael Woudenberg P.Eng. (Age 53)
    VP of Chemistry, Manufacturing & Controls
  • Dr. Sazzad Hossain
    Co-Founder
  • Mr. Brendan Payne
    Director of Investor Relations
  • Mr. Richard Hoy
    VP of Sales & Marketing
  • Dr. Ado Muhammad
    Sr. Consultant of Medical Affairs

IMLFF Stock Analysis - Frequently Asked Questions

How have IMLFF shares performed in 2024?

InMed Pharmaceuticals' stock was trading at $0.4160 at the beginning of the year. Since then, IMLFF shares have decreased by 39.4% and is now trading at $0.2520.
View the best growth stocks for 2024 here
.

How do I buy shares of InMed Pharmaceuticals?

Shares of IMLFF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:IMLFF) was last updated on 4/26/2024 by MarketBeat.com Staff

From Our Partners